Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: A survey of barriers and enablers

2013 ◽  
Vol 21 (5) ◽  
pp. 262-267 ◽  
Author(s):  
Jocelyn M. Williams ◽  
Martin R. Jude ◽  
Christopher R. Levi
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Recombinant Tissue Plasminogen Activator ◽  
Barriers And Enablers ◽  
Tissue Plasminogen

Thrombolysis in Acute Ischaemic Stroke Pathway

2008 ◽  
Vol 12 (2) ◽  
pp. 10-22
Author(s):  
Samuel Chew ◽  
Shahid A Kausar ◽  
Steve Sturman
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Clinical Excellence ◽  
Recombinant Tissue Plasminogen Activator ◽  
Acute Period ◽  
Management Of Complications ◽  
Tissue Plasminogen

Thrombolysis of appropriate and selected patients presenting with an acute ischaemic stroke within 3 h of onset with recombinant Tissue Plasminogen Activator (alteplase, r-TPA) can be implemented safely, reduce long-term disability, and is recommended by the National Institute of Health and Clinical Excellence and the Department of Health's National Stroke Strategy. We have developed an integrated and comprehensive pathway in order to achieve the above aims, which also provide guidelines for nursing in the peri-acute period and management of complications arising from the ischaemic stroke itself, from thrombolysis or from concomitant hyperglycaemia.

scholarly journals A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke

2017 ◽  
Vol 2 (2) ◽  
pp. 73-83 ◽  
Author(s):  
Heesoo Joo ◽  
Guijing Wang ◽  
Mary G George
Keyword(s):  
Cost Effectiveness ◽  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Cost Effective ◽  
Recombinant Tissue Plasminogen Activator ◽  
Tissue Plasminogen ◽  
The Cost ◽  
Effectiveness Studies

BackgroundIntravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for patients with acute ischaemic stroke, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischaemic stroke is not well reviewed.AimsTo conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times.Summary of reviewA literature search was conducted using MEDLINE, EMBASE, CINAHL and Cochrane Library, with the keywords acute ischemic stroke, tissue plasminogen activator, cost, economic benefit, saving and incremental cost-effectiveness analysis. The review is limited to original research articles published during 1995–2016 in English-language peer-reviewed journals. We found 16 studies meeting our criteria for this review. Nine of them were cost-effectiveness studies of IV rtPA treatment within 0–3 hours after stroke onset, 2 studies within 3–4.5 hours, 3 studies within 0–4.5 hours and 2 studies within 0–6 hours. IV rtPA is a cost-saving or a cost-effectiveness strategy from most of the study results. Only one study showed incremental cost-effectiveness ratio of IV rtPA within 1 year was marginally above US$50 000 per quality-adjusted life year threshold. IV rtPA within 0–3 hours after stroke led to cost savings for lifetime or 30 years and IV rtPA within 3–4.5 hours after stroke increased costs but still was cost-effective.ConclusionsThe literature generally showed that IV rtPA was a dominant or a cost-effective strategy compared with traditional treatment for patients with acute ischaemic stroke without IV rtPA. The findings from the literature lacked generalisability because of limited data and various assumptions.

scholarly journals Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

The Lancet ◽  
2012 ◽  
Vol 379 (9834) ◽  
pp. 2364-2372 ◽  
Author(s):  
Joanna M Wardlaw ◽  
Veronica Murray ◽  
Eivind Berge ◽  
Gregory del Zoppo ◽  
Peter Sandercock ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Meta Analysis ◽  
Recombinant Tissue Plasminogen Activator ◽  
Tissue Plasminogen
Sign in / Sign up

Export Citation Format

Share Document